Sibling Oocyte Study of Medium for In Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) With no Human Serum Albumine
Information source: Sykehuset Telemark
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: In Vitro Fertilization; Infertility
Intervention: Medium with no human serum albumine added (Other); Conventional medium (Other)
Phase: Phase 2
Sponsored by: Sykehuset Telemark
Official(s) and/or principal investigator(s):
Jarl Kahn, Dr. Med, Study Director, Affiliation: Fertilitetsklinikken Sør
The purpose of this study is to determine if a new medium with no human serum albumine added
is as good as the media conventionally used for IVF/ICSI.
Official title: Sibling Oocyte Study of Medium for IVF/ICSI With no Human Serum Albumine
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Cells attained in IVF/ICSI procedures are kept in a medium that nurture the cells. Until now
all such media have contained human serum albumine. The purpose of this study is to
determine if a new medium with no human serum albumine added is as good as the media
conventionally used for IVF/ICSI.
Minimum age: 18 Years.
Maximum age: 38 Years.
- Couples seeking IVF/ICSI.
- Female under 38 years of age.
- No more than two previous IVF/ICSI treatments without pregnancy.
- Regular menstruation periods.
- No endocrine disease that requires treatment in the female.
- BMI below 30 in the female.
- At least 8 mature follicles upon monitoring or 6 MII oocytes upon ICSI.
- Written informed consent.
- Low responders to FSH.
- Females in danger of developing OHSS.
- Sperm sample below ICSI-quality.
Locations and Contacts
Fertilitetsklinikken Sør, Porsgrunn, Telemark 3901, Norway
Starting date: September 2007
Last updated: May 19, 2015